ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2232

Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort

Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Nicole Wilson5, Susan Manzi5, Veena Joy6 and Tyler O'Malley7, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6ThermoFisher, Philadelphia, PA, 7Exagen, Vista, CA

Meeting: ACR Convergence 2024

Keywords: Anti-CCP, Autoantibody(ies), Biomarkers, Cohort Study, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity to provide greater diagnostic and treatment certainty among patients with inflammatory arthritis. Anti-RA33 Ab have demonstrated high specificity for RA in a pair of European RA cohorts [Sieghart D, Platzer A, Studenic P, et al. Front Immunol. 2018;9:876]. The present study aims to empirically derive cutoffs for novel anti-RA33 immunoassays and determine the performance characteristics in a U.S. cohort enriched for SN-RA.

Methods: A cohort of 377 subjects consisting of 161 RA subjects meeting 2010 ACR classification criteria, 87 SLE meeting 1997 ACR classification criteria, 73 apparently healthy volunteers (AHV), 28 clinically diagnosed Sjögrens and 28 clinically diagnosed psoriatic arthritis (PsA) subjects were consented for Ab screening. Enzyme-linked fluorescent immunoassay testing was performed on the Phadia (Thermo Scientific) system to measure anti-CCP2 IgG, RF (IgA and IgM) and anti-RA33 (IgA, IgG and IgM). Cutoffs for anti-CCP and RF were based on manufacturer’s specifications. Anti-RA33 autoantibody cutoffs for each isotype were set above the 95th percentile of AHVs. RA subjects testing negative for anti-CCP and RF IgM and IgA were considered SN-RA for the purposes of analysis. Chi-square analysis was performed to compare frequency of RA33 autoantibodies stratified by disease duration, age and RA disease activity reflected by clinical disease activity index (CDAI) category.

Results: The SN-RA cohort (N = 101) was majority white (83%), female (85%) with a mean (SD) age of 60 (± 10) years (Table 1). A combined 16% were positive for one or more anti-RA33 Ab with IgA, IgG and IgM present in 5%, 9% and 7%, respectively (Fig. 1A). Of the 16 SN-RA subjects testing anti-RA33 positive, 12 (75%) were positive for a single isotype. The seropositive RA (SP-RA) cohort (N = 60) was similar: majority white (80%), female (80%) with a mean age of 60 (± 10) years. A combined 32% were positive for one or more anti-RA33 Ab with IgA, IgG and IgM present in 9%, 10% and 22%, respectively (Fig. 1B). Anti-RA33 IgG was 99% specific for RA vs. AHV, while IgM and IgA were 96% and 95% specific, respectively (Table 2). In the other autoimmune disease groups, anti-RA33 specificity for RA was generally > 90% except for IgG Ab which were 85% specific for RA vs. SLE and IgA and IgM isotypes (86% specific vs. PsA). The frequency of anti-RA33 Ab stratified by disease duration (early [0-2 years since diagnosis], established [2-10 years], and longstanding [ >10 years]), age (>50 vs. < 50 years old) and CDAI categories (remission and low vs. moderate and high) were not significantly different (p > 0.05) for either SP-RA or SN-RA.

Conclusion: The data indicate that while anti-RA33 Ab are present in a significant proportion of SN-RA patients, their prevalence does not appear to vary significantly with disease duration, age, or disease activity. The integration of anti-RA33 Ab measurement with other SN-RA biomarkers may mitigate diagnostic uncertainty in early inflammatory arthritis and attenuate treatment delays.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Concoff: Exagen, Inc., 3, 11, Pacira Biosciences, inc., 2, United Rheumatology, A Specialty Networks Company, 2, 4; T. Warsi: Exagen Inc., 3; S. Taghavi: Exagen, 3; S. Kumar: EXAGEN INC, 3; A. Patalinghug: Exagen, 3; C. Schleif: Exagen Inc., 3; B. Partain: Exagen, 3; J. Ahearn: Exagen, 1, 2, 5, 6, 9, 10; N. Wilson: None; S. Manzi: AstraZeneca, 2, 5, BMS, 5, Cartesian, 2, 5, Exagen Diagnostics, Inc., 2, 9, 10, GSK, 2, 5, Lilly, 2, Lupus Foundation of America, 4, Miltenyi, 12, DSMB, Tenet, 2, UCB, 1, 2; V. Joy: Thermo Fisher Scientific, 3; T. O'Malley: Exagen, 3, 11.

To cite this abstract in AMA style:

Concoff A, Warsi T, Taghavi S, Kumar S, Patalinghug A, Schleif C, Partain B, Ahearn J, Wilson N, Manzi S, Joy V, O'Malley T. Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/anti-ra33-autoantibodies-are-unique-sensitive-biomarkers-for-the-identification-of-seronegative-rheumatoid-arthritis-in-a-u-s-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-ra33-autoantibodies-are-unique-sensitive-biomarkers-for-the-identification-of-seronegative-rheumatoid-arthritis-in-a-u-s-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology